Gapping down
In reaction to earnings/guidance:
- HAYW -5.4%, PHG -4.1%
Other news:
- OPK -11.1% (Opko Health and Pfizer (PFE) receive Complete Response Letter for BLA for somatrogon)
- PLTK -6.9% (largest stockholder exploring potential sale of a portion of its shares of Playtika)
- VKTX -6.8% (FDA places Phase 1b clinical trial of VK0214 on clinical hold)
- CIAN -6.6% (announced that it has entered into an agreement for the acquisition of SmartDeal)
- DQ -4.5% (provided estimate of its subsidiary net profit; proposes offering of RMB11 Billion in ordinary shares for its 100,000 MT polysilicon expansion project in China) SBSW -4.1% (Sibanye-Stillwater subsidiary gave notice of termination of the Atlantic Nickel SPA)
- MRNA -3.7% (vaccine stocks under pressure after COVID data takes positive turn)
- ABUS -3.7% (2022 Corporate Objectives and Provides Financial Update)
- PFE -3.5% (vaccine stocks under pressure after COVID data takes positive turn)
- NMG -3.4% (files prospectus supplement establishing a new at-the-market equity offering)
- BNTX -3.4% (vaccine stocks under pressure after COVID data takes positive turn)
- LEE -1.8% (Files Definitive Proxy Statement and Sends Letter to Shareholders)
Analyst comments:
- SNAP -5.3% (downgraded to Neutral from Outperform at Wedbush)
- FHB -1.7% (downgraded to Neutral from Buy at Compass Point)
- EVTC -1% (downgraded to Neutral from Positive at Susquehanna)